Gibbs Wealth Management Grows Stake in Thermo Fisher Scientific Inc. $TMO

Posted by Brenda Bartman on Jul 24th, 2026

Gibbs Wealth Management lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 300.8% in the 1st quarter, Holdings Channel reports. The firm owned 3,074 shares of the medical research company’s stock after acquiring an additional 2,307 shares during the period. Gibbs Wealth Management’s holdings in Thermo Fisher Scientific were worth $1,511,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Howard Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after acquiring an additional 16 shares during the period. Petros Family Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 3.9% during the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 17 shares during the last quarter. Salomon & Ludwin LLC lifted its position in Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after purchasing an additional 17 shares during the period. Pallas Capital Advisors LLC grew its position in Thermo Fisher Scientific by 1.5% in the 4th quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after purchasing an additional 18 shares during the period. Finally, Red Door Wealth Management LLC raised its stake in Thermo Fisher Scientific by 0.8% during the 4th quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock valued at $1,250,000 after buying an additional 18 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $573.43 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The stock has a market cap of $213.10 billion, a price-to-earnings ratio of 31.52, a PEG ratio of 2.33 and a beta of 0.87. The company’s 50 day moving average is $491.42 and its two-hundred day moving average is $513.08.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TMO. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $606.45.

View Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, ahead of the $5.71 consensus, with revenue of $11.99 billion also topping estimates. Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today
Positive Sentiment: Management raised full-year FY2026 guidance, with EPS and revenue outlooks both coming in above Wall Street expectations, signaling confidence in continued demand and execution. Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights
Positive Sentiment: Improving customer activity across end markets and continued organic growth helped ease investor concerns about a prolonged slowdown in medical research and tools demand. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
Neutral Sentiment: Separately, Thermo Fisher was selected by ImmuPharma to help manufacture its Kapiglucagon diabetes candidate, a modest business development update that supports the company’s CDMO pipeline but is not likely to move shares on its own. ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.